Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update
Y Wang, YJ Chang, J Chen, M Han, JD Hu, J Hu… - Cancer Letters, 2024 - Elsevier
The consensus in 2018 from The Chinese Society of Haematology (CSH) on the monitoring,
treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell …
treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell …
Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not
achieve molecular complete remission or who subsequently relapse are not cured by …
achieve molecular complete remission or who subsequently relapse are not cured by …
Analysis benefits of a second allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
X Cao, J Zhang, Y Zhao, M Xiong, J Zhou, Y Lu… - Frontiers in …, 2023 - frontiersin.org
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial
complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients …
complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients …
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
P Chauvet, A Paviglianiti, M Labopin… - Bone marrow …, 2023 - nature.com
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation
X Cao, J Li, P Lu, K Liu - International Journal of Hematology, 2022 - Springer
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for B-
cell acute lymphoblastic leukemia (B-ALL). Although allo-HSCT can be curative for some B …
cell acute lymphoblastic leukemia (B-ALL). Although allo-HSCT can be curative for some B …
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
I Varadarajan, E Pierce, L Scheuing… - OncoTargets and …, 2023 - Taylor & Francis
Allogeneic hematopoietic cell transplantation (allo-HCT) represents an important and
potentially curative treatment option for adult patients with acute lymphoblastic leukemia …
potentially curative treatment option for adult patients with acute lymphoblastic leukemia …
Immune Therapies of B-cell Acute Lymphoblastic Leukaemia in Children and Adults
D Kegyes, G Ghiaur, A Bancos, C Tomuleasa… - Critical Reviews in …, 2024 - Elsevier
ABSTRACT B-cell acute lymphoblastic leukaemia (B-cell ALL) is a common haematologic
cancer in children and adults. About 10 percent of children and 50 percent of adults fail to …
cancer in children and adults. About 10 percent of children and 50 percent of adults fail to …
Novel mechanism and strategies to overcome relapse after allogeneic stem cell transplantation
Y Sun, X Zhang, L Hu, MB Abid - Frontiers in Immunology, 2023 - frontiersin.org
The curative potential of allogeneic hematopoietic stem cell transplant (allo-HCT) for
hematologic malignancies and nonmalignant conditions was first explored during the 1950s …
hematologic malignancies and nonmalignant conditions was first explored during the 1950s …
Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?
KM Kállay, M Algeri, J Buechner, AC Krauss - Frontiers in Pediatrics, 2022 - frontiersin.org
This review will address the place of innovative, non-chemotherapy, non-CAR-T targeted
therapies in the treatment of Acute Lymphoblastic Leukaemia (ALL), focusing on their use in …
therapies in the treatment of Acute Lymphoblastic Leukaemia (ALL), focusing on their use in …
[HTML][HTML] Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART …
SM Huang, CL Wan, HY Cao, YY Li, CS Qian… - Clinical Case …, 2023 - ncbi.nlm.nih.gov
The prognosis of adult relapse or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
is dismal, with a complete remission rate of approximately 18%–44% if receiving salvage …
is dismal, with a complete remission rate of approximately 18%–44% if receiving salvage …